Now Playing
Opinion|Videos|June 20, 2024
Treatment Sequencing and Unmet Needs in HR+/HER2-Low Metastatic Breast Cancer
Author(s)Aditya Bardia, MD, MPH, Laura Huppert, MD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, discuss treatment sequencing practices and ongoing challenges in patients with HR+/HER2-low breast cancer.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- For patients who no longer benefit from prior endocrine therapy, what is your current approach to treatment sequencing in HR+/HER2-low metastatic breast cancer?
- What are some unmet needs and ongoing challenges in patients with HR+/HER2-low breast cancer?
Advertisement
Related to this article
Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5